Human papilloma virus: from understanding of immunopathogenesis to rational tactics of management

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (3) ◽  
pp. 5-11 ◽  
Author(s):  
A L Tikhomirov ◽  
S I Sarsaniya ◽  
G A Filatova
Keyword(s):  
Human Papilloma Virus ◽  
Sexually Transmitted Infection ◽  
Hpv Infection ◽  
Sexually Active ◽  
Transmitted Infection ◽  
Papilloma Virus ◽  
Sexually Transmitted ◽  
Active Population ◽  
The World ◽  
Epithelial Lesions

The human papilloma virus (HPV) is the most common sexually transmitted infection. 440 million people in the world suffer from HPV infection of the genital. During the life of HPV, 50 to 80% of the sexually active population is infected, most often in the first years of sexual activity (the maximum prevalence is between 18-30 years of age). The treatment of subclinical forms of HPV epithelial lesions in 115 patients aged 26 to 42 years with a normal colposcopic pattern and the presence of coilocytosis was performed.

scholarly journals Knowledge and Health Beliefs of Nursing Students Toward Human Papilloma Virus and Vaccine Use

2019 ◽  
Vol 4 (2) ◽  
pp. 27-32
Author(s):  
Fatjona Kamberi ◽  
Eva Muhaj
Keyword(s):  
Nursing Students ◽  
Human Papilloma Virus ◽  
Health Beliefs ◽  
Perceived Risk ◽  
Hpv Infection ◽  
Statistical Association ◽  
Transmitted Infection ◽  
Cross Sectional ◽  
Papilloma Virus ◽  
Sexually Transmitted

Objective: Human Papilloma Virus (HPV) infection is the most common sexually transmitted among young people of both sexes. It is also the main cause of cervical cancer. This study aimed at assessing students’ knowledge and health beliefs about HPV infection and the use of the vaccine.Methods: The sample of the cross-sectional study was 120 randomly selected nursing students from the Faculty of Public Health, University of Vlore “Ismail Qemali” Albania. Anonymous, self-administered questionnaire based on the literature and Health Belief Model, was used for data collection in May 2017. The questionnaire included assessment questions for students’ knowledge and health beliefs about HPV and vaccine use. Also, questions about socio-demographic characteristics were included. Data analysis included the calculation of averages, frequencies, and confidence intervals. P values ≤0.05 were accepted as statistically significant.Result: Mean age 20.3±2.2 years, 92.44 % of students were female. 65.83% of students know that HPV is a sexually transmitted infection and a vaccine is available to prevent it. Ambiguities and uncertainties exist in regard to screening with Pap test after vaccination. Perceived benefits are high for 50.83% of students. Perceived severity appeared low as only 25% of students agree that they may be affected by HPV. Statistical association, p =0.0347 was found between perceived risk and the year of study. The parents’ role in vaccination against HPV have a strong statistical association, p=0.0058 with the year of study as only 8.33 % of students in the third year agree with the fact that that parents do not allow them to be vaccinated against HPV. Conclusion: The study noted the student’s ambiguity and misconceptions about HPV infection. Low severity and lack of knowledge about the vaccine emphasizes that identifying their current level of knowledge and the main source of information are essential to provide comprehensive and appropriate health education.

scholarly journals Giant Genital Condyloma Acuminatum: A case report

2021 ◽  
Author(s):  
Poojan Thakor ◽  
Mohit Kumar Badgurjar ◽  
Giriraj Prajapati ◽  
Pankaj Saxena ◽  
Suman Parihar
Keyword(s):  
Case Report ◽  
Human Papilloma Virus ◽  
Sexually Transmitted Infection ◽  
Treatment Options ◽  
Condyloma Acuminatum ◽  
High Rate ◽  
Lower Abdomen ◽  
Transmitted Infection ◽  
Papilloma Virus ◽  
Sexually Transmitted

Abstract The giant condyloma acuminatum(GCA),also known as Buschke–Löwenstein tumor(BLT),is a type of human papilloma virus associated sexually transmitted infection. Various treatment options are available but best option amongst them is surgery. This case report present a GCA case in male with masses over lower abdomen and penile region where surgical resection is done, taking into account the high rate of recurrence and the significant potential of malignant transformation.

scholarly journals Genotyping of Human Papilloma Virus (HPV) in female condyloma acuminata patient in Dr. Soetomo Hospital, Surabaya

2019 ◽  
Author(s):  
Afria Arista ◽  
Dwi Murtiastutik ◽  
Trisniartami Setyaningrum ◽  
Gondo Mastutik
Keyword(s):  
Human Papilloma Virus ◽  
Hpv Infection ◽  
Cross Sectional Study ◽  
Condyloma Acuminata ◽  
Multiple Infection ◽  
Transmitted Infection ◽  
Cross Sectional ◽  
Papilloma Virus ◽  
Sexually Transmitted ◽  
Polymerase Chain

Human Papilloma Virus (HPV) cause the most common sexually transmitted infection in women. HPV may lead to clinical manifestation as condyloma acuminata. The type of HPV are divided into two categories: low risk and high risk. Objective: To determine the type of HPV in female condyloma acuminata patient. Material and methods: A cross sectional study was conducted in Dermatology Venereology Outpatient Clinic Dr. Soetomo Hospital Surabaya from February, 2007 to May, 2007. A total of 13 female patients with condyloma acuminata were includ in this study. Nucleic acids amplification assays (Polymerase Chain Reaction) used to detect the HPV infection. Results: Condyloma acuminata mostly caused by HPV-11 (30,76%) and HPV-6 (23,07%). Only 1 patient in this study caused by HPV 18. 38% of condyloma acuminata in this study caused by multiple infection of HPV. Conclusion: Molecular assay are gold standard to identification of HPV in the condyloma acuminata patient.

scholarly journals Human Papilloma Virus Vaccination

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1091
Author(s):  
Kendal Rosalik ◽  
Christopher Tarney ◽  
Jasmine Han
Keyword(s):  
Human Papilloma Virus ◽  
Vaccine Development ◽  
Developed Countries ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Papilloma Virus ◽  
Sexually Transmitted ◽  
Worldwide Distribution ◽  
Vaccine Distribution ◽  
Global Population

Human papilloma virus (HPV) is the most common sexually transmitted infection worldwide causing a variety of benign and malignant conditions. A significant portion of the global population is infected with HPV, with the virus attributed to causing up to 5% of cancers worldwide. Bivalent, quadrivalent, and nine-valent vaccinations exist to aid in the prevention of these diseases and have been proven to be effective at preventing both benign and malignant disease. While vaccination is readily accessible in more developed countries, barriers exist to worldwide distribution and acceptance of vaccination. Vaccination and screening of HPV infection when used in combination are proven and predicted to decrease HPV related pathology. Improvements in vaccination formulations, for treatment as well as prevention, are actively being sought from a variety of mechanisms. Despite these advancements, and the data supporting their efficacy, there has been substantial delay in obtaining adequate vaccination coverage. In reviewing these challenges and looking forward to new vaccine development—especially within the current pandemic—it is clear from the challenges of HPV we require methods to more effectively encourage vaccination, ways to dispel vaccination myths as they occur, and implement better processes for vaccine distribution globally.

scholarly journals 1641. A Comparison of Human Papilloma Virus Infection Prevalence Trends Pre- and Post-HPV Vaccine Implementation

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S599-S599
Author(s):  
Patrick Ovie. Fueta ◽  
Onyema Greg Chido-Amajuoyi
Keyword(s):  
United States ◽  
Human Papilloma Virus ◽  
Hpv Vaccine ◽  
Human Papilloma Virus Infection ◽  
The United States ◽  
Hpv Infection ◽  
Infection Prevalence ◽  
Transmitted Infection ◽  
Papilloma Virus ◽  
The Impact

Abstract Background Human papilloma virus (HPV) is the most common sexually transmitted infection in the United States, with an annual incidence rate of approximately 14 million people. The HPV vaccine has been demonstrated to be highly effective in the prevention of HPV infection and HPV-associated diseases. This study aims to evaluate the impact of HPV vaccine on the prevalence of HPV infection in the United States and evaluate the trends of disease prevalence pre- and post-HPV vaccine implementation. Methods We conducted a secondary data analysis of the National Health and Education Survey (NHANES) for trends in HPV infection from 2003 to 2016. The analysis was grouped into a pre-HPV vaccine implementation (2003–2006) cohort including 4064 females, aged 18–59 years; and a post-HPV vaccine implementation (2007–2016) cohort which included 10718 females, aged 18–59 years. Further analysis of HPV infection prevalence, pre- and post-HPV vaccine implementation, stratified by sociodemographic characteristics were conducted. Results The prevalence of HPV infection prior to HPV vaccine implementation was 43.98% (95 CI 42.71%–46.58%) compared with 40.55% (95 C.I 40.55%–40.56%) in the post-HPV vaccine implementation era. Among females with HPV infections in the post-HPV vaccine implementation cohort 82.6 (95% CI 80.41%–83.42%) were unvaccinated. In both cohorts, black females had a significantly higher prevalence of HPV with a prevalence rate of 18.56% (95% CI 18.23%–20.56%) in the pre-HPV vaccine implementation cohort, and 15.61% (95% CI 14.82 – 19.4%) in the post-HPV vaccine implementation cohort. Females with less than high school education had a higher prevalence of HPV in the pre and post- HPV vaccine implementation cohorts with prevalence rates of 25.77% (95% CI 23.44%–28.72%) and 24.96% (95% CI 23.41%–25.67%), respectively. Conclusion The results suggest that HPV infection prevalence has declined since the implementation of HPV vaccine to US national immunization program. Our findings highlight disparities in HPV infection prevalence by race and educational status, and these patterns are in keeping with HPV-associated disease such as warts and HPV-associated cancers. Disclosures All authors: No reported disclosures.

scholarly journals Epidemiology of Anal HPV Infection in High-Risk Men Attending a Sexually Transmitted Infection Clinic in Puerto Rico

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e83209 ◽  
Author(s):  
Vivian Colón-López ◽  
Ana Patricia Ortiz ◽  
Lizbeth Del Toro-Mejías ◽  
Michael Craig Clatts ◽  
Joel M. Palefsky
Keyword(s):  
Puerto Rico ◽  
High Risk ◽  
Sexually Transmitted Infection ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Sexually Transmitted Infection Clinic ◽  
Infection Clinic

Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years

2020 ◽  
Vol 24 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Alex Derstenfeld ◽  
Kyle Cullingham ◽  
Zhuo Cai Ran ◽  
Ivan V. Litvinov
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Older Men ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Control And Prevention

Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.

scholarly journals Mouthwash-Based Highly Sensitive Pyro-Genotyping for Nine Sexually Transmitted Human Papilloma Virus Genotypes

2020 ◽  
Vol 21 (10) ◽  
pp. 3697
Author(s):  
Yoshiyuki Watanabe ◽  
Yukiko Seto ◽  
Ritsuko Oikawa ◽  
Takara Nakazawa ◽  
Hanae Furuya ◽  
...  
Keyword(s):  
Conventional Method ◽  
Hpv Infection ◽  
Oral Sex ◽  
Transmitted Infection ◽  
Simple Method ◽  
Papilloma Virus ◽  
Sexually Transmitted ◽  
Highly Sensitive ◽  
Virus Genotypes ◽  
Oral Hpv

Human papillomavirus (HPV) is a common sexually transmitted infection worldwide, which spreads via contact with infected genital, anal, and oral/pharyngeal areas (oral sex) owing to diverse manners of sexual intercourse. In this study, we devised an oral HPV detection method using mouthwash waste fluids that causes less psychological resistance to visiting the outpatient otolaryngology departments. We successfully detected only the specific unique reverse sequencing probe (using pyro-genotyping) and identified the nine genotypes of HPV targeted for vaccination by pyrosequencing the mouthwash waste fluids of non-head and neck cancer patient volunteers (n = 52). A relatively large number (11/52) of mouthwash waste fluids tested positive for HPV (21.2%; genotype 6, n = 1; 11, n = 1; 16, n = 1; and 18, n = 8). These results surpassed the sensitivity observed testing the same specimens using the conventional method (1/52, 1.9%). Our method (pyro-genotyping) was developed using nine HPV genotypes targeted for vaccination and the results were highly sensitive compared to those of the conventional method. This less expensive, high-throughput, and simple method can be used for detecting oral HPV infection with fewer socio-psychological barriers.

Sign in / Sign up

Export Citation Format

Share Document